Menu

Cochrane Collaboration Expels Cofounder, Prompts Resignations

Physician Peter Gøtzsche, a board member of the organization, has been an outspoken critic of certain vaccines and of the pharma industry in general.

Sep 18, 2018
Catherine Offord

ABOVE: Peter Gøtzsche has previously described big pharma as “organized crime.”
YOUTUBE, JOHN MCDOUGALL

Update (September 20): The Cochrane Collaboration issued a statement yesterday (September 19) stating that the board’s decision is “not about freedom of speech” (emphasis Cochrane’s). Instead, “it is about a long-term pattern of behaviour that we say is totally, and utterly, at variance with [Cochrane’s] principles and governance.” In accordance with the organizations rules, Gøtzsche for now remains a member, and has seven days to make a written response. “We will report back to you about the outcome as soon as we are able to,” the statement says. 

The Cochrane Collaboration, a respected medical organization that conducts systematic reviews of research and helps guide clinical practice, has expelled one of its governing board members, Danish physician and Cochrane cofounder Peter Gøtzsche, STAT News reported yesterday (September 16). The grounds for the decision, which led to the resignations of several other board members who had voted against the move, have not yet been made public, but the resulting controversy has cast a cloud over the organization’s 2018 annual meeting, now underway in Edinburgh in the UK. 

Gøtzsche, also the director of the Nordic Cochrane Center, has suggested that the decision was motivated by Cochrane’s disapproval of his challenges to the pharmaceutical industry and frequent criticism of the vaccines it manufactures. “As most people know, much of my work is not very favourable to the financial interests of the pharmaceutical industry,” he writes in a letter published online on Friday (September 14). “Because of this Cochrane has faced pressure, criticism, and complaints. My expulsion is one of the results of these campaigns.”

See “Mammography Article Withdrawal Sparks Dispute

In July of this year, he and two colleagues published a critique of a recent Cochrane review of multiple human papillomavirus (HPV) vaccine trials. The organization’s review had concluded that prophylactic vaccines were safe and effective at preventing cervical precancer in young women. Gøtzsche and his colleagues argued in their paper that the review had failed to include key clinical trials, and was skewed by several sources of bias. 

According to Hilda Bastian, another of the Cochrane Collaboration’s founders, Gøtzsche’s critique was itself flawed, STAT reports. She called the article “a hatchet job by people with several axes to grind,” in a blog post last month. “I would be surprised if Cochrane’s investigation and update resulted in changed conclusions.” Cochrane later issued its own statement supporting the original review and disputing Gøtzsche and his colleagues’ criticisms. 

The expulsion of an elected member of the board has created heated debate among scientists, both within and outside the organization. Of the 13-person board, six voted in favor of Gøtzsche’s expulsion and two did not vote, STAT reports. According to a statement published on Saturday (September 15) on Cochrane’s website, four board members have since resigned as a result of the decision.

“We consider the Board’s use of its authority to expel Peter from Cochrane to be disproportionate,” wrote the four members in a statement, Science reports. “We believe that the expulsion of inconvenient members from the Collaboration goes against Cochrane ethos and neither reflects its founding spirit nor promotes the Collaboration’s best interests.”

In an email thread among experts in evidence-based medicine, Allen Frances, chair of the department of psychiatry at Duke University, writes that the debate has “nothing to do with freedom of speech,” STAT reports. “At least in psychiatry, Peter is anything but impartial,” he continues. “He consistently expresses the most extreme views in the most dramatic and misleading way. . . . As an individual, Peter has total freedom to express extreme opinions, but he has no inherent right to cloak them with Cochrane’s hard won mantle of neutrality.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.